Date: 2014-01-28
Type of information: R&D agreement
Compound:
Company: Curie-Cancer (France) Servier (France)
Therapeutic area: Cancer - Oncology
Type agreement: R&D
Action mechanism:
Disease: ‘triple negative’ breast cancers
Details: * On January 28, 2014, Curie-Cancer, which leads the Institut Curie\'s industry partner research activity, and Servier have announced that they have renewed their partnership with the aim of identifying therapeutic targets for treating ‘triple negative’ breast cancers. The partnership will continue for a further three years. The partners will share the intellectual property resulting from this work.
As early as 2005, the Institut Curie and Servier decided to pool their expertise to identify potential therapeutic targets specific to triple negative breast cancers, using the Institut Curie\'s extensive collection of breast cancer samples. The goal of the initial partnership was to identify molecules that act on these targets, in order to develop medicinal products to improve treatment for patients who do not respond to the current therapies available. The work undertaken over the last few years has involved many doctors and researchers: highly specialised biologists, biochemists, geneticists and bioinformaticians from both the Institut Curie and Servier. They have discovered a number of very promising leads, identifying a therapeutic target, kinase TTK/MPS1, an enzyme involved in cell cycle regulation. A medicinal product that acts on this target is already in preclinical development.
Financial terms:
Latest news:
